Address: Scheurlstraße 21 ,D-90478 Nürnberg Postbox 440138
Tel: +49 (0) 911 946469-0
Founded in 1998 by Daniel M. Perlman, RPS implemented its business plan to build the industry’s first Pharmaceutical Resource Organization model. The RPS plan was dedicated to achieving the goal of providing the biopharmaceutical industry with an alternative to traditional outsourcing models by offering customized, integrated solutions that addressed these fundamental industry challenges.The European growth of RPS allows clients to utilize the market leading integrated clinical solutions and enhanced full-service capabilities of RPS to develop clinical products beyond the Americas and into Europe for greater value generation across a global R&D pipeline. RPS recently acquired three CROs in Europe: in Germany, France and Spain. RPS entered the German market in December 2008, when they acquired Imerem GmbH. RPS has acquired Imerem’s specialist knowledge in major indications of clinical indications: CNS (neurology and psychiatry), oncology (solid, hematological tumors), transplantation, pain, dermatology. We are highly experienced in studies with phytomedicines and complementary medicinal treatments, medicinal products, and large-scale post-marketing surveillance studies. Imerem was in particular the world-wide leading CRO in research in the “Restless Legs Syndrome.”Executive Vice President of Clinical Operations in Europe and CEO of RPS Germany is Dr. Ralf Kohnen, former founder of Imerem GmbH.
Oskar Möbert, vice president of Veeva OpenData, discusses how standardizing customer reference data and systems organization-wide can help biopharmas scale globally and become more agile in their business. Data…
The biggest pharma industry and healthcare stories from Germany, including the country’s legalisation of cannabis; the MASH potential of Boehringer Ingelheim’s obesity candidate; Bayer’s further share price drop and expansion…
Pharma is rushing to adopt AI-driven tools in the hope of revolutionizing everything from drug discovery to clinical trials, regulatory submissions, and marketing efforts. While AI is the technology du…
Susanne Schaffert’s over 20-year stint at Novartis culminated with her presidency of the Swiss giant’s global oncology division, but when the company underwent a major restructure in 2022, she found…
As head of digital transformation at Bayer, Saskia Steinacker is well placed to unpack the hype around artificial intelligence in healthcare. In a wide-ranging interview, she explains how AI is…
Rainer Westermann of venture capitalist coalition Life Sciences Acceleration Alliance reviews the potential impact of the EU’s general pharmaceutical legislation on the investment climate for the EU life sciences sector.…
The latest pharma industry news from Germany, including Lilly’s new German plant; Bayer’s aborted anti-clotting drug trial and legal worries; Boehringer Ingelheim’s acquisition of Swiss biotech T3 Pharmaceuticals, and Hermes…
After positions at Novartis and Merck, Bettina Bauer, a trained scientist, joined Gilead in 2019 as VP and general manager of its German affiliate. Today, as the VP of the…
Merck’s Kaushal Kishore attempts to illustrate why pharma companies have struggled to crack what he calls “the Gross to Net (GtN) code.” He outlines the maturity journey for a pharma…
Patents can be an excellent way to demonstrate value, not only showing that a technology is protected but also how promising it can be when it eventually comes to market.…
The rise of niche therapies is shaping a more tailored engagement model, driven by data and AI, writes Florian Schnappauf, vice president of enterprise commercial strategy at Veeva Europe. …
Following the COVID-19 pandemic and the resulting supply chain disruptions, global drug pricing and access reforms have multiplied. The Inflation Reduction Act (IRA) has been introduced in the US while…
See our Cookie Privacy Policy Here
